SERAXIS INC has a total of 45 patent applications. Its first patent ever was published in 2013. It filed its patents most often in Australia, EPO (European Patent Office) and Israel. Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are PRIMEGEN BIOTECH LLC, NOVOCELL INC and UNIVERSITATSKLINIKUM HAMBURG E.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 5 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | Israel | 5 | |
#4 | United States | 5 | |
#5 | Canada | 4 | |
#6 | China | 4 | |
#7 | Republic of Korea | 4 | |
#8 | Singapore | 4 | |
#9 | WIPO (World Intellectual Property Organization) | 4 | |
#10 | Brazil | 2 | |
#11 | EAPO (Eurasian Patent Organization) | 1 | |
#12 | India | 1 | |
#13 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Measurement | |
#5 | Macromolecular chemistry and polymers |
# | Name | Total Patents |
---|---|---|
#1 | Rust William L | 37 |
#2 | William L Rust | 3 |
Publication | Filing date | Title |
---|---|---|
KR20200128409A | Cells, devices and methods of use for macro-encapsulation therapy | |
US2021008122A1 | Pancreatic cells for treating diabetes and methods of generating the same | |
KR20190133708A | Macro-encapsulated therapeutic cells and methods of use thereof | |
SG11201408717XA | Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus |